Novo Nordisk A/S (NVO)vsTotalEnergies SE ADR (TTE)
NVO
Novo Nordisk A/S
$42.96
-1.81%
HEALTHCARE · Cap: $194.70B
TTE
TotalEnergies SE ADR
$89.40
+0.78%
ENERGY · Cap: $195.51B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 78% more annual revenue ($327.80B vs $183.96B). NVO leads profitability with a 37.2% profit margin vs 8.2%. TTE appears more attractively valued with a PEG of 0.72. NVO earns a higher WallStSmart Score of 73/100 (B).
NVO
Strong Buy73
out of 100
Grade: B
TTE
Strong Buy72
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 60 in profit
Keeps 37 of every $100 in revenue as profit
Strong operational efficiency at 61.6%
Earnings expanding 67.1% YoY
Generating 12.0B in free cash flow
Earnings expanding 57.1% YoY
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.3%
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
3.4% revenue growth
Grey zone — moderate risk
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.
Bull Case : TTE
The strongest argument for TTE centers on EPS Growth, Market Cap, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio.
Bear Case : TTE
The primary concerns for TTE are Revenue Growth, Altman Z-Score, Piotroski F-Score.
Key Dynamics to Monitor
NVO profiles as a growth stock while TTE is a value play — different risk/reward profiles.
NVO carries more volatility with a beta of 0.35 — expect wider price swings.
NVO is growing revenue faster at 24.0% — sustainability is the question.
NVO generates stronger free cash flow (12.0B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (73/100 vs 72/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
TotalEnergies SE ADR
ENERGY · OIL & GAS INTEGRATED · USA
TotalEnergies SE is a global integrated oil and gas company. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?